Renin-angiotensin system inhibitors initiation and mortality in non-proteinuric chronic kidney disease: a target trial emulation
Clinical Kidney Journal · 02.11.2026 · 19 (11)
DOI: 10.1093/ckj/sfag285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 28.10.2026. Verfasst von Fan Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Disease, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Insti…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Technologies R&D Program of Guangdong Province, Guangdong Provincial Clinical Research, Program of Introducing Talents of Discipline to Universities.
Abstract (Originalsprache)
Background
Treatment options for nonproteinuric chronic kidney disease (CKD) are limited. While renin-angiotensin system inhibitors (RASIs) are cornerstone therapies for proteinuric CKD, evidence supporting the clinical benefit of RASIs initiation in nonproteinuric CKD is lacking.
Methods
We emulated sequential target trials using a retrospective cohort from the China Renal Data System. Adults with nonproteinuric CKD (urine albumin-to-creatinine ratio <30 mg/g) were included to assess the intention-to-treat effect of initiating RASIs on all-cause and cardiovascular mortality. The primary estimate was the 3-year risk difference. A composite kidney outcome (>25% eGFR decline with stage deterioration or kidney replacement therapy) was also explored.
Results
A total of 17 382 eligible person-trials (10 101 unique persons) were included. The 3-year cumulative incidence of all-cause mortality was 14.88% (95% confidence interval [CI], 13.65% to 16.51%) and 18.26% (95% CI, 17.67% to 19.42%) in the RASIs initiation group and the control group, respectively, corresponding to a risk difference of −3.39% (95% CI, −4.71% to −2.07%). A significant association favoring RASIs initiation was also observed in terms of cardiovascular mortality, with a 3-year risk difference of −1.46% (95%CI, −2.57% to −0.52%). Estimates from the subgroup and the sensitivity analyses were consistent with the primary analysis. A similar trend of association was observed for composite kidney outcomes, though the 3-year cumulative risk difference between groups did not reach statistical significance (risk difference, −0.88%; 95% CI, −2.42%–1.40%).
Conclusions
Initiation of RASIs may be associated with lower risks of all-cause and cardiovascular mortality in patients with nonproteinuric CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Kidney Disease, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failu…
ORCID-Profile: Ruixuan Chen, Xin Xu, Sheng Nie
Förderung
- Key Technologies R&D Program of Guangdong Province
- Guangdong Provincial Clinical Research
- Program of Introducing Talents of Discipline to Universities
- National Natural Science Foundation of China
Zitieren
APA
Luo, F., Jin, L., Zhou, S., Chen, R., Pang, M., Lin, Y., Li, Y., Su, L., Xu, X., Nie, S., & Hou, F. F. (2026). Renin-angiotensin system inhibitors initiation and mortality in non-proteinuric chronic kidney disease: a target trial emulation. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag285
Vancouver
Luo F, Jin L, Zhou S, Chen R, Pang M, Lin Y, et al. Renin-angiotensin system inhibitors initiation and mortality in non-proteinuric chronic kidney disease: a target trial emulation. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag285
BibTeX
@article{Luo2026,
author = {Luo, Fan and Jin, Luhua and Zhou, Shiyu and Chen, Ruixuan and Pang, Mingzhen and Lin, Yuxin and Li, Yanqin and Su, Licong and Xu, Xin and Nie, Sheng and Hou, Fan Fan},
title = {Renin-angiotensin system inhibitors initiation and mortality in non-proteinuric chronic kidney disease: a target trial emulation},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {11},
doi = {10.1093/ckj/sfag285}
}
EUVIMED